

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

# Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia ID6347

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company  Autolus (obecabtagene autoleucel)  Patient/carer groups  African Caribbean Leukaemia Trust  Anthony Nolan  Black Health Agency for Equality  Blood Cancer UK  Cancer 52  Cancer Black Care  Cancer Equality	<ul> <li>General</li> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health - Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Hospital Information Services –</li> </ul>
<ul> <li>Chronic Lymphocytic Leukaemia Support Association</li> <li>DKMS</li> <li>Helen Rollason Cancer Charity</li> <li>Independent Cancer Patients Voice</li> <li>Kevin Kararwa Leukaemia Trust</li> <li>Leukaemia Cancer Society</li> <li>Leukaemia Care</li> <li>Macmillan Cancer Support</li> <li>Maggie's Centres</li> <li>Marie Curie</li> </ul>	Jehovah's Witnesses  Medicines and Healthcare products Regulatory Agency  National Association of Primary Care  National Pharmacy Association  NHS Confederation  Scottish Medicines Consortium  Welsh Government  Welsh Health Specialised Services Committee
<ul> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Tenovus Cancer Care</li> <li>WMUK</li> </ul>	<ul> <li>Possible comparator companies</li> <li>AAH Pharmaceuticals (dasatinib, imatinib)</li> <li>Accord UK (cytarabine, filgrastim, fludarabine, imatinib, pegfilgrastim</li> </ul>
<ul> <li>Healthcare professional groups</li> <li>Association of Anaesthetists</li> <li>Association of Cancer Physicians</li> <li>Association of Surgeons of Great Britain and Ireland</li> <li>British Blood Transfusion Society</li> <li>British Geriatrics Society</li> <li>British Institute of Radiology</li> </ul>	<ul> <li>Amarox (imatinib)</li> <li>Amgen (blinatumomab, filgrastim, pegfilgrastim)</li> <li>Chugai Pharma UK Ltd (lenograstim)</li> <li>Cipla EU (imatinib)</li> <li>Consilient Health (clofarabine)</li> <li>Dr. Reddy's Laboratories (imatinib)</li> <li>Hospira UK (cytarabine)</li> <li>Incyte Biosciences UK (ponatinib)</li> </ul>

Provisional stakeholder list for the evaluation of obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia ID6347



#### **Provisional Consultees Provisional Commentators (no right to** submit or appeal) **British Oncology Pharmacy** Milpharm (imatinib) Association Mylan (dasatinib) British Psychosocial Oncology Society Napp Pharmaceuticals (pegfilgrastim) British Society for Haematology Neon Healthcare (clofarabine) British Society of Blood and Marrow Novartis (imatinib, tisagenlecleucel) Transplantation and Cellular Therapy Pfizer (cytarabine, filgrastim, idarubicin, **British Transplantation Society** inotuzumab ozogamicin) British Society of Interventional Sandoz (dasatinib, filgrastim, imatinib, Radiology pegfilgrastim) Cancer Research UK Sanofi (fludarabine) NHS Blood and Transplant Teva UK (dasatinib, fludarabine, Royal College of General Practitioners lipegfilgrastim) Tillomed Laboratories (clofarabine) Royal College of Nursing Royal College of Pathologists Viatris UK Healthcare (dasatinib) Royal College of Physicians Zentiva (dasatinib) Royal College of Radiologists Royal Pharmaceutical Society Relevant research groups Cochrane Haematological Group Royal Society of Medicine Genomics England Society and College of Radiographers Institute of Cancer Research **UK Clinical Pharmacy Association** Leukaemia Busters **UK Oncology Nursing Society** Leukaemia UK Lymphoma Research Trust Others Department of Health and Social Care MRC Clinical Trials Unit **NHS** England National Institute for Health Research Associated Public Health groups Public Health Wales **UK Health Security Agency**


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

### Consultees

Provisional stakeholder list for the evaluation of obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia ID6347 Issue date: July 2024



Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.